REGN - Regeneron Pharmaceuticals, Inc.

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
390.19
-0.09 (-0.02%)
At close: 4:00PM EDT

390.28 +0.09 (0.02%)
After hours: 5:00PM EDT

Stock chart is not supported by your current browser
Previous Close390.28
Open387.29
Bid360.00 x 1000
Ask395.00 x 1000
Day's Range385.95 - 393.80
52 Week Range281.89 - 477.00
Volume366,160
Avg. Volume744,426
Market Cap42.119B
Beta1.77
PE Ratio (TTM)28.33
EPS (TTM)13.77
Earnings DateNov 6, 2018 - Nov 12, 2018
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est406.05
Trade prices are not sourced from all markets
  • CHMP Reconfirms Negative Opinion for Sarepta's Exondys
    Zacks4 hours ago

    CHMP Reconfirms Negative Opinion for Sarepta's Exondys

    The CHMP re-confirmed the negative opinion for Sarepta's (SRPT) Exondys, which is developed to treat individuals who have a specific type of Duchenne muscular dystrophy.

  • Novartis Gets Positive CHMP Opinion for Drugs, Biosimilar
    Zacks5 hours ago

    Novartis Gets Positive CHMP Opinion for Drugs, Biosimilar

    Novartis (NVS) gets positive CHMP opinion for a label expansion of Gilenya, gene therapy, and a biosimilar of Neulasta.

  • FDA Confirms Positive Safety Profile of Acadia's Nuplazid
    Zacks3 days ago

    FDA Confirms Positive Safety Profile of Acadia's Nuplazid

    Acadia's shares soar more than 20% as the FDA issues a statement reaffirming the positive benefit-risk profile of Nuplazid for patients with Parkinson's disease psychosis.

  • Shire’s Quarterly Revenue Trend
    Market Realist4 days ago

    Shire’s Quarterly Revenue Trend

    Biotechnology company Shire (SHPG) reported a 4.6% YoY (year-over-year) rise in revenue to ~$3.9 billion in the second quarter compared to $3.7 billion in the second quarter of 2017.

  • The 7 Best Biotech Stocks for Investors Who Hate Risk
    Kiplinger4 days ago

    The 7 Best Biotech Stocks for Investors Who Hate Risk

    Most of the buy-and-hold crowd tends to steer clear of biotech stocks, and for good reason. Biotechnology companies can be uncomfortably risky. Far too many horror stories of failed drug trials or the expiration of a crucial patent leading to massive stock plunges have circulated for years now, souring would-be buyers on the entire industry. However, conclusions based on a handful of biotech stocks may have erroneously prevented investors from plugging into a perfectly reasonable risk-reward relationship. Said differently: Not all biotech stocks turn into disasters. The industry as a group is up nearly 70% for the past five years, proving many of these companies can reward patient shareholders who choose wisely. It's simply a matter of doing your homework and having a little common sense. Here are seven biotech stocks that aren't nearly as risky as their typical peer. Thus, they may have a place in more risk-averse portfolios than most investors might presume. SEE ALSO: The 25 Best Stocks to Buy (According to Hedge Funds)

  • Zacks.com highlights: G-III Apparel Group, Target, Regeneron Pharmaceuticals, AMETEK and Xilinx
    Zacks5 days ago

    Zacks.com highlights: G-III Apparel Group, Target, Regeneron Pharmaceuticals, AMETEK and Xilinx

    Zacks.com highlights: G-III Apparel Group, Target, Regeneron Pharmaceuticals, AMETEK and Xilinx

  • The Zacks Analyst Blog Highlights: Regeneron Pharmaceuticals, Celgene, Sanofi and Gilead Sciences
    Zacks5 days ago

    The Zacks Analyst Blog Highlights: Regeneron Pharmaceuticals, Celgene, Sanofi and Gilead Sciences

    The Zacks Analyst Blog Highlights: Regeneron Pharmaceuticals, Celgene, Sanofi and Gilead Sciences

  • Benzinga5 days ago

    5 Stocks Primed To Fall Lower In The Coming Days

    The following stocks are currently in the midst of various stages of downtrends according to VantagePoint, an AI charting platform that uses intermarket analysis and artificial intelligence to predict future price action 1-3 days in advance. For a more detailed look at VantagePoint's charts, click here. Square Inc (NYSE: SQ) has ripped in 2018, rising 140 percent year-to-date. Not only has the blue line completely converged with the black line, but the neural index at the bottom of the chart is squarely (no pun intended) in the red and has been for several days.

  • Biotech Stock Roundup: CELG, REGN Present Data, VKTX Soars on Drug's Success
    Zacks5 days ago

    Biotech Stock Roundup: CELG, REGN Present Data, VKTX Soars on Drug's Success

    Pipeline updates and data read-outs at the 27th European Academy of Dermatology and Venereology (EADV) Congress in France comprise some of the key developments in the biotech sector this week.

  • 5 Stocks Near 52-Week High With Scope for Further Upside
    Zacks5 days ago

    5 Stocks Near 52-Week High With Scope for Further Upside

    Here are some stocks trading near their 52-week high levels with room for further improvement.

  • Regeneron Gains on Eylea, Dupixent and Pipeline Progress
    Zacks6 days ago

    Regeneron Gains on Eylea, Dupixent and Pipeline Progress

    Solid performance of approved drugs like Eylea and Dupixent along with an encouraging pipeline progress improve Regeneron's (REGN) market position.

  • Reuters7 days ago

    Sanofi pledges to keep up its restructuring efforts

    Sanofi (SASY.PA) will continue to implement cost savings after having reached a 1.5 billion euros (£1.3 billion) cost reduction target a year ahead of expectations, and added that several of its key drugs were selling well. "It's only the beginning, and we will continue to be very efficient," Chief Executive Olivier Brandicourt told investors, regarding the cost savings, at a Bank of America Merrill Lynch conference in London on Friday. The CEO did not elaborate further but referred to a reorganisation of Sanofi's global business units unveiled earlier this week.

  • Regeneron-Sanofi Report Data on Dupixent in Atopic Dermatitis
    Zacks7 days ago

    Regeneron-Sanofi Report Data on Dupixent in Atopic Dermatitis

    Regeneron (REGN) and partner Sanofi present encouraging data from a late-stage trial on dermatitis drug Dupixent in adolescents.

  • Time to Focus on Regeneron Pharmaceuticals (REGN) for Strong Earnings Growth Potential
    Zacks7 days ago

    Time to Focus on Regeneron Pharmaceuticals (REGN) for Strong Earnings Growth Potential

    Regeneron Pharmaceuticals (REGN) seems well-positioned for future earnings growth and it is seeing rising earnings estimates as well, coupled with a solid Zacks Rank.

  • See what the IHS Markit Score report has to say about Regeneron Pharmaceuticals Inc.
    Markit10 days ago

    See what the IHS Markit Score report has to say about Regeneron Pharmaceuticals Inc.

    Regeneron Pharmaceuticals Inc NASDAQ/NGS:REGN

  • GlobeNewswire10 days ago

    Sanofi: Positive Phase 3 results presented for Dupixent® (dupilumab)

    September 15, 2018 - Detailed results from a pivotal Phase 3 trial showed Dupixent® (dupilumab) monotherapy demonstrated a significant improvement in signs and symptoms of atopic dermatitis and certain quality of life measures in adolescent patients (12-17 years) with moderate-to-severe atopic dermatitis, whose disease was inadequately controlled with topical therapies or for whom topical treatment was medically inadvisable. There continues to be a significant unmet need for adolescents with moderate-to-severe atopic dermatitis, whose disease cannot be controlled with topical treatments. Dupixent is currently approved for use in certain adult patients with moderate-to-severe atopic dermatitis in countries including the U.S., European Union, Canada and Japan.

  • PR Newswire10 days ago

    Positive Phase 3 Results Presented for Dupixent® (dupilumab) Show Significant Improvement on Multiple Measures of Disease Severity in Adolescents with Moderate-to-Severe Atopic Dermatitis

    Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) and Sanofi today presented detailed results from a pivotal Phase 3 trial showing Dupixent® (dupilumab) monotherapy demonstrated a significant improvement in signs and symptoms of atopic dermatitis and certain quality of life measures in adolescent patients (12-17 years) with moderate-to-severe atopic dermatitis, whose disease was inadequately controlled with topical therapies or for whom topical treatment was medically inadvisable. There continues to be a significant unmet need for adolescents with moderate-to-severe atopic dermatitis, whose disease cannot be controlled with topical treatments. Dupixent is currently approved for use in certain adult patients with moderate-to-severe atopic dermatitis in countries including the U.S., European Union, Canada and Japan.

  • Sanofi pledges to keep up its restructuring efforts
    Reuters11 days ago

    Sanofi pledges to keep up its restructuring efforts

    Sanofi (SASY.PA) will continue to implement cost savings after having reached a 1.5 billion euros (1.33 billion pounds) cost reduction target a year ahead of expectations, and added that several of its key drugs were selling well. "It's only the beginning, and we will continue to be very efficient," Chief Executive Olivier Brandicourt told investors, regarding the cost savings, at a Bank of America Merrill Lynch conference in London on Friday. The CEO did not elaborate further but referred to a reorganisation of Sanofi's global business units unveiled earlier this week.

  • Analyzing Regenxbio’s Valuation Metrics
    Market Realist11 days ago

    Analyzing Regenxbio’s Valuation Metrics

    Regenxbio (RGNX) generated revenues, chiefly from licensing, of $40.03 million in the second quarter compared to $6.56 million in Q2 2017. For fiscal 2018, Regenxbio is expected to generate revenues of $194.55 million compared to $10.39 million in fiscal 2017. The increase in revenues helped Regenxbio generate a net income of $10.59 million in the second quarter compared to a net loss of $14.47 million in the second quarter of 2017.

  • PR Newswire12 days ago

    FDA to Review EYLEA (aflibercept) Injection for the Treatment of Diabetic Retinopathy

    TARRYTOWN, N.Y., Sept. 13, 2018 /PRNewswire/ -- Regeneron Pharmaceuticals, Inc. (REGN) today announced that the U.S. Food and Drug Administration (FDA) has accepted for review the supplemental Biologics License Application (sBLA) of EYLEA® (aflibercept) Injection for the treatment of diabetic retinopathy (DR), the leading cause of vision loss for patients with diabetes. The sBLA submission is based on results from the Phase 3 PANORAMA trial investigating EYLEA as a treatment for patients with moderately severe to severe non-proliferative diabetic retinopathy (NPDR) without diabetic macular edema (DME).

  • Bluebird Bio Stock May Have Upside of at Least 60 Percent
    InvestorPlace12 days ago

    Bluebird Bio Stock May Have Upside of at Least 60 Percent

    Just as Bluebird Bio (NASDAQ:BLUE) started gaining traction in the markets in August, the stock erased all those gains since the start of September. And the month is hardly over. Why did BLUE stock fall 12% last week when the company did not issue any news that would explain what changed, fundamentally?

  • Biotech Stock Roundup: GILD's Arthritis Drug Successful in Phase III, PRQR Soars
    Zacks12 days ago

    Biotech Stock Roundup: GILD's Arthritis Drug Successful in Phase III, PRQR Soars

    Pipeline updates and collaborating agreement comprise some of the key developments in the biotech sector this week.

  • Regeneron/Sanofi's sBLA for Praluent to be Reviewed by FDA
    Zacks12 days ago

    Regeneron/Sanofi's sBLA for Praluent to be Reviewed by FDA

    The FDA will review Regeneron (REGN) and Sanofi's sBLA for its PCSK9 Inhibitor Praluent to reduce risk of major adverse cardiovascular events.

  • PR Newswire13 days ago

    FDA to review supplemental Biologics License Application for Praluent® (alirocumab) Injection as potential treatment to reduce major adverse cardiovascular events

    /PRNewswire/ -- Sanofi and Regeneron Pharmaceuticals, Inc. announced that the U.S. Food and Drug Administration (FDA) has accepted a supplemental Biologics License Application (sBLA) for Praluent® (alirocumab) Injection, a PCSK9 inhibitor. The sBLA outlines a proposed update to the Prescribing Information to include the effect of Praluent in reducing the overall risk of major adverse cardiovascular events (MACE).

  • GlobeNewswire13 days ago

    FDA to review supplemental Biologics License Application for Praluent® (alirocumab) Injection as potential treatment to reduce major adverse cardiovascular events

    September 12, 2018 - Sanofi and Regeneron Pharmaceuticals, Inc. announced that the U.S. Food and Drug Administration (FDA) has accepted a supplemental Biologics License Application (sBLA) for Praluent® (alirocumab) Injection, a PCSK9 inhibitor. The sBLA outlines a proposed update to the Prescribing Information to include the effect of Praluent in reducing the overall risk of major adverse cardiovascular events (MACE).